Dose-finding and -expansion studies of trastuzumab deruxtecan in combination with other anti-cancer agents in patients (pts) with advanced/metastatic HER2+ (DESTINY-Breast07 [DB-07]) and HER2-low (DESTINY-Breast08 [DB-08]) breast cancer (BC)

MLA

Fabrice Andre, et al. “Dose-Finding and -Expansion Studies of Trastuzumab Deruxtecan in Combination with Other Anti-Cancer Agents in Patients (Pts) with Advanced/Metastatic HER2+ (DESTINY-Breast07 [DB-07]) and HER2-Low (DESTINY-Breast08 [DB-08]) Breast Cancer (BC).” Journal of Clinical Oncology, vol. 40, June 2022, p. 3025. EBSCOhost, https://doi.org/10.1200/jco.2022.40.16_suppl.3025.

APA

Fabrice Andre, Erika P. Hamilton, Sherene Loi, Seock-Ah Im, Joohyuk Sohn, Ling-Ming Tseng, Carey K. Anders, Peter Schmid, Sarice Boston, Annie Darilay, Pia Maarit Herbolsheimer, Adam Konpa, Gargi Patel, Tinghui Yu, Magdalena Wrona, & Komal L. Jhaveri. (2022). Dose-finding and -expansion studies of trastuzumab deruxtecan in combination with other anti-cancer agents in patients (pts) with advanced/metastatic HER2+ (DESTINY-Breast07 [DB-07]) and HER2-low (DESTINY-Breast08 [DB-08]) breast cancer (BC). Journal of Clinical Oncology, 40, 3025. https://doi.org/10.1200/jco.2022.40.16_suppl.3025

Chicago

Fabrice Andre, Erika P. Hamilton, Sherene Loi, Seock-Ah Im, Joohyuk Sohn, Ling-Ming Tseng, Carey K. Anders, et al. 2022. “Dose-Finding and -Expansion Studies of Trastuzumab Deruxtecan in Combination with Other Anti-Cancer Agents in Patients (Pts) with Advanced/Metastatic HER2+ (DESTINY-Breast07 [DB-07]) and HER2-Low (DESTINY-Breast08 [DB-08]) Breast Cancer (BC).” Journal of Clinical Oncology 40 (June): 3025. doi:10.1200/jco.2022.40.16_suppl.3025.